EuBiologics Co., Ltd.

As of June 30, 2026, EuBiologics Co., Ltd. carries a market capitalization of 317.66B, placing it among publicly traded companies globally. Its enterprise value stands at 253.40B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

EuBiologics Co., Ltd.'s next confirmed earnings release is scheduled for November 6, 2026.

As of June 30, 2026, EuBiologics Co., Ltd. has 36.72M shares outstanding.

As of June 30, 2026, EuBiologics Co., Ltd. trades at a trailing price-to-earnings ratio of 10.94. The price-to-sales ratio is 2.60, and the price-to-book ratio stands at 1.75.

As of June 30, 2026, EuBiologics Co., Ltd. trades at an EV/EBITDA multiple of 4.74 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.07 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 5.85 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. EuBiologics Co., Ltd. trades at an EV/FCF ratio of 38.32, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 253.40B versus a market cap of 317.66B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, EuBiologics Co., Ltd. maintains a current ratio of 3.97, meaning it holds 4.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.01, indicating elevated leverage, while an interest coverage ratio of 66.25 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, EuBiologics Co., Ltd. posted a return on equity (ROE) of 17.19, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 16.82 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 12.52, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 17.12, useful for judging operating efficiency across full business cycles. The company generates approximately 316.87M in revenue per employee across its workforce of 386.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.59 indicates how many times EuBiologics Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, EuBiologics Co., Ltd. recorded 13.95B in income tax expense. That works out to an effective tax rate of 32.48, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 42.96B, leaving 29.00B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, EuBiologics Co., Ltd.'s stock has declined approximately 43.18% over the past 52 weeks. The 50-day moving average sits at 8,533.60, while the 200-day moving average is 10,769.30.

Over the twelve months ended June 30, 2026, EuBiologics Co., Ltd. generated 122.31B in revenue and converted that into 29.00B in net income, yielding earnings per share of 789.83. EBITDA reached 53.48B, while operating income came in at 43.29B.

As of June 30, 2026, EuBiologics Co., Ltd. holds 67.92B in cash and equivalents against 3.66B in total debt, resulting in a net debt position of -13.98B. Total book value stands at 181.52B, with working capital of 104.92B providing operational flexibility.

EuBiologics Co., Ltd. produced 22.47B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -16.40B in capital expenditures, free cash flow totaled 6.07B - equivalent to 165.36 per share.

Over the twelve months ended June 30, 2026, EuBiologics Co., Ltd. posted a gross margin of 58.67, reflecting its pricing power and cost economics. The operating margin of 35.39 and net profit margin of 23.71 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 1.91, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 1.89, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to EuBiologics Co., Ltd. shareholders.

EuBiologics Co., Ltd.'s most recent stock split took place on November 12, 2020 with a 962:995 split ratio.

As of June 30, 2026, EuBiologics Co., Ltd. has an Altman Z-Score of 5.87, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.